Article
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
Nature - 1 Aug 2022
Wang Qian, Guo Yicheng, Iketani Sho, Nair Manoj S, Li Zhiteng, Mohri Hiroshi, Wang Maple, Yu Jian, Bowen Anthony D, Chang Jennifer Y, Shah Jayesh G, Nguyen Nadia, Chen Zhiwei, Meyers Kathrine, Yin Michael T, Sobieszczyk Magdalena E, Sheng Zizhang, Huang Yaoxing, Liu Lihong, Ho David D
Abstract excerpt
SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have surged notably to become dominant in the United States and South Africa, respectively1,2. These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies, thereby further compromising the efficacy of COVID-19 vaccines and therapeutic monoclonals. We now report findings from a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.